Sanofi settles dispute with Genzyme investors over MS drug

Sanofi has settled a long-running dispute with shareholders in the biotech Genzyme, who claimed the big pharma deliberately held back development of a multiple sclerosis drug to avoid payme

Biogen bags FDA okay for Tecfidera follow-up Vumerity

Getting MS diagnosis right

MS advocate Trishna Bharadia explains how diagnosis needs to change and why pharma shouldn’t be using the word ‘patient’.

Janssen's MS pill outshines Sanofi's Aubagio in phase 3 tria...

Johnson & Johnson’s Janssen unit has announced phase 3 results showing that its ponesimod tablet outperformed Sanofi’s Aubagio pill in adults with relapsing multiple sclerosis.

Novartis strikes marketing deal for Polpharma's potential Ty...

Novartis’ biosimilars and generics arm Sandoz has struck a deal with Polpharma Biologics to market a proposed biosimilar of Biogen’s multiple sclerosis drug Tysabri (natalizumab).<

Novartis looks set to repurpose cancer drug in MS after tria...

Novartis has announced data supporting a cancer drug it acquired from GlaxoSmithKline and Genmab in a new use in multiple sclerosis, with plans for regulatory filings later this year.